A Phase 3 interventional study of Hemay005 tablet and Placebo in Ulcerative Colitis (UC), sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 183 studies in Colitis, Ulcerative with a site in China — 72 open to participants now, 95 under way, 25 of them phase 3. Colitis, Ulcerative · China.
Among the 183 studies in Colitis, Ulcerative with a site in China, this one is the 29th largest by planned enrollment of the 135 interventional ones that give a count, is one of 28 that started in 2026, is one of 32 in phase 3, reaches primary completion later than 67 of the 94 other live ones, and was the 170th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →72 of the 183 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:
Accro Bioscience (Suzhou) Limited · Sites in China
Ages 18–75
Nanjing Immunophage Biotech Co., Ltd · Sites in China
Ages 18–70
Second Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 18+
The Second Hospital of Nanjing Medical University · Sites in China
Ages 18–75
Innatus Therapeutics (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
183 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 46 · Phase 3 37 · Phase 4 11
First in 2009; this study’s year is marked. 28 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 120 across the 135 interventional studies, 176 across the 48 observational. Of the 58 that completed or were terminated, 15 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 183 have an industry lead sponsor. The 10 most frequent:
Ganzhou Hemay Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
Ganzhou Hemay Pharmaceutical Co., Ltd has 2 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
26 of the studies in Colitis, Ulcerative with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
Add all 26 to your calendar (.ics) → With an account.
Among the 183 studies in Colitis, Ulcerative with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with moderately to severely active ulcerative colitis.
This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety of Hemay005 in induction and maintenance therapy in Chinese patients with moderately or severely active ulcerative colitis. The study consists of two independent phases: an 12-week Induction Phase (might including an 12-week Extended Induction phase, depending on the participant status by the end of the induction treatment) and a 40-week Maintenance Phase. Screening period will be up to 5 Weeks.
In the Induction Phase, participants will be randomized 2:1 to receive either Hemay005 (twice daily) or placebo for 12 weeks. The randomization will be stratified by: exposed to advanced therapy (yes/no); disease severity (modified Mayo score of 5-6 or 7-9) and baseline corticosteroid use (yes/no). Participants who have not show clinical response (either receive Hemay005 or placebo) by week 12 will undergo an extended 12-week induction treatment with Hemay005.
After completing the Induction Phase (or the Extended Induction Phase), participants with response are eligible to go to the Maintenance Phase. Participants with a response to Hemay005 by week 12 of the Induction Phase and those with a response by the end of the Extended Induction Phase) will be randomized 1:1 to receive either Hemay005 (twice daily) or placebo for 40 weeks. Randomization will be stratified by corticosteroid use at the start date of Maintenance Phase (yes/no) and clinical remission status by the end of Induction Phase (yes/no). Participants who are assigned to placebo during the Induction Phase and have demonstrated a clinical response will continue to receive blinded placebo during the Maintenance Phase. Participants who have not showed a clinical response by week 12 of the Induction Phase but have a response to Hemay005 by the end of the Extended Induction Phase will continue to receive blinded Hemay005 during the Maintenance Phase.
During the Maintenance Phase, participants who are demonstrated loss of response will be eligible to go to the open-label treatment phase and treated with Hemay005. The total duration of open-label treatment phase will not exceed 40 weeks since the participant enrolled into the Maintenance Phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Demonstrated inadequate response, loss of response and/or intolerance to at least one of the following UC therapies:
A) Conventional therapies, including oral 5-aminosalicylic acid (5-ASA) compounds, , immunoregulatory agents.
B) Advanced therapies: biologics (including but not limit to antitumor necrosis factor alpha (TNFα) antibodies, anti-integrin antibodies, anti-interleukin 12/23 antibodies) and small molecule therapies(including but not limit to JAK inhibitors, S1P receptor modulators) Note: The medication used to qualify the subject for entry into this category must be approved for the treatment of UC in the country of use and the subject must have received an adequate course of therapy based on local guidelines for that therapy.
Exclusion Criteria:
Severe UC as evidenced by any of the following:
A) Hospitalization for the treatment of UC ≤ 2 weeks prior to screening or, in the physician's judgement, is likely to require hospitalization for medical care or surgical intervention of any kind for UC during the study.
B)Current evidence of fulminant colitis, toxic megacolon, or recent history (within 6 months) of toxic megacolon, or bowel perforation.
C)Prior history of subtotal, or total colectomy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60mg, administratered orally, twice daily
Drug: Hemay005 tablet
matching tablet, administratered orally, twice daily
Drug: Placebo
60mg, administratered orally, twice daily
Drug: Hemay005 tablet
matching tablet, administratered orally, twice daily
Drug: Placebo
Participants receive treatment with Hemay005 tablet during the Induction Phase (week I-0\~I-12).
Participants receive treatment with placebo tablet during the Induction Phase (week I-0\~I-12).
Participants receive treatment with Hemay005 tablet during the Maintenance Phase (week M-0\~M-40).
Participants receive treatment with placebo during the Maintenance Phase (week M-0\~M-40).
Induction Phase: Percentage of Participants With Clinical Remission at Week 12.
Clinical remission is based on the Modified Mayo Score (mMS). The Modified Mayo Score (mMS) consists of Rectal Bleeding Subscore (RBS), Stool Frequency Subscore (SFS) and Mayo Endoscopic Subscore (MES). Each subscore ranges from 0 to 3 and a total mMS ranging from 0 to 9, with higher scores indicating more severe disease. Clinical remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline , and a RBS of 0, and a MES of 0 or 1 without friability.
Time frame: Induction Phase Week 12
Maintenance Phase: Percentage of Participants With Clinical Remission at Week 40.
Clinical remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline , and a RBS of 0, and a MES of 0 or 1 without friability.
Time frame: Maintenance Phase: Week 40
Induction Phase: Percentage of Participants With Endoscopic Improvement at Week 12.
Endoscopic Improvement is based on the Mayo Endoscopic Subscore (MES). The MES ranges from 0 to 3, with higher scores indicating more severe disease. Endoscopic Improvement is defined as MES of 0 or 1(without friability).
Time frame: Induction Phase: At Week 12
Induction Phase: Percentage of Participants With Completely Symptomatic Remission at Week 12.
Complete Symptomatic Remission is defined as a SFS of 0 and a RBS of 0.
Time frame: At Week 12
Induction Phase: Percentage of Participants With Symptomatic Remission at Week 12.
Symptomatic Remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline and a RBS of 0.
Time frame: At Week 12
Induction Phase: Percentage of Participants With Clinical Response at Week 12.
Clinical response is based on the Modified Mayo Score (mMS). The Modified Mayo Score (mMS) consists of Rectal Bleeding Subscore (RBS), Stool Frequency Subscore (SFS) and Mayo Endoscopic Subscore (MES). Each subscore ranges from 0 to 3 and a total mMS ranging from 0 to 9, with higher scores indicating more severe disease. Clinical Response is defined as a decrease in mMS of at least 2 points and 30% from baseline and either a decrease of at least 1 in RBS or a RBS of 0 or 1.
Time frame: At Week 12
Induction Phase: Percentage of Participants With Endoscopic Response at Week 12.
Endoscopic Response is defined as a decrease of at least 1 in MES from baseline.
Time frame: At Week 12
Induction Phase: Percentage of Participants With Symptomatic Response at Week 12.
Symptomatic Response is defined as a a decrease of ≥30% in the sum of RBS and SFS from baseline.
Time frame: At Week 12
Maintenance Phase: Percentage of Participants With Endoscopic Improvement at Week 40.
Endoscopic Improvement is defined as MES of 0 or 1 (without friability).
Time frame: At Week 40
Maintenance Phase: Percentage of Participants with a Clinical Remission both at Week 12 of Induction Phase and Week 40 of Maintenance Phase.
Clinical remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline , and a RBS of 0, and a MES of 0 or 1 without friability.
Time frame: At Week 40
Maintenance Phase: Percentage of Participants With Steroid-free Clinical Remission at Week 40.
Steroid-free Clinical Remission is defined as achieving clinical remission and have not used corticosteroids to treat UC for at least 8 weeks.
Time frame: At Week 40
Maintenance Phase: Percentage of Participants With Endoscopic Response at Week 40.
Endoscopic Response is defined as a decrease of at least 1 in MES from baseline.
Time frame: At Week 40
Maintenance Phase: Percentage of Participants with a Clinical Response both at Week 12 of Induction Phase and Week 40 of Maintenance Phase.
Clinical Response is defined as a decrease in mMS of at least 2 points and 30% from baseline and either a decrease of at least 1 in RBS or a RBS of 0 or 1.
Time frame: At Week 40
Maintenance Phase: Percentage of Participants With Complete Symptomatic Remission.
Complete Symptomatic Remission is defined as a SFS of 0 and a RBS of 0.
Time frame: Maintenance Phase: At Week 8, Week 16, Week 24, Week 32, Week 40.
Maintenance Phase: Percentage of Participants With Symptomatic Remission.
Symptomatic Remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline and a RBS of 0.
Time frame: Maintenance Phase: At Week 8, Week 16, Week 24, Week 32, Week 40.
Maintenance Phase:Percentage of Participants With Symptomatic Response.
Symptomatic Response is defined as a a decrease of ≥30% in the sum of RBS and SFS from baseline.
Time frame: Maintenance Phase: At Week 8, Week 16, Week 24, Week 32, Week 40.
Change of calprotectin from baseline.
Time frame: At Week 12 of Induction Phase and Week 40 of Maintenance Phase.
Among participants with abnormal calprotectin at baseline, percentage of participant with normalized calprotectin.
Time frame: At Week 12 of Induction Phase and Week 40 of Maintenance Phase.
Change of modified Mayo score from baseline.
The Modified Mayo Score (mMS) consists of Rectal Bleeding Subscore (RBS), Stool Frequency Subscore (SFS) and Mayo Endoscopic Subscore (MES). Each subscore ranges from 0 to 3 and a total mMS ranging from 0 to 9, with higher scores indicating more severe disease.
Time frame: At Week 12 of Induction Phase and at Week 40 of Maintenance Phase.
Change of partial modified Mayo score from baseline.
The partial modified Mayo Score (pmMS) consists of Rectal Bleeding Subscore (RBS) and Stool Frequency Subscore (SFS). Both RBS and SFS range from 0 to 3, with higher scores indicating more severe disease.
Time frame: Induction Phase: At Week 2, Week 4, Week 8, Week 12. Maintenance Phase: At Week 8, Week 16, Week 24, Week 32, Week 40.
Change of IBDQ score from baseline.
The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
Time frame: At Week 12 of Induction Phase and at Week 40 of Maintenance Phase.
Among participants with abnormal C-reactive protein at baseline, percentage of participant with normalized C-reactive protein.
Time frame: At Week 12 of Induction Phase and at Week 40 of Maintenance Phase.
Incidence and Severity of Adverse Events, Serious Adverse Events, Adverse Events Leading to Discontinuation, Adverse events of Special Interest.
Time frame: From Week 0 of Induction Phase to Week 40 of Maintenance Phase
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for May 2028, 23 months later.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 23 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hemay005
Ganzhou Hemay Pharmaceutical Co., Ltd